The Latest

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    A new BioPharma Dive analysis shows that, in 2026, drugmakers are paying considerably more for rights to China-based medicines than they were last year.

    Updated 4 hours ago
  • psychedelic brain
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    Psychedelics developer Definium scores more positive data for LSD pill

    Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

  • An illustration of lymphocytes
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Boulevard starts up with $65M to pursue targeted autoimmune drugs

    Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    At least seven biotechs have announced venture fundings since Monday, representing the busiest calendar week in two months among the investment firms BioPharma Dive tracks.

    Updated Aug. 13, 2026
  • President Trump holding up an executive order on vaccines.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip
    Vaccines

    Trump signs order seeking to upend childhood vaccine schedule

    The executive order — which wasn’t accompanied by any new scientific evidence — aims to split the MMR vaccine into three separate shots and revives the administration’s attempt to slim down the immunization schedule.

    FDA
  • A close-up of a child's hands with red, irritated skin on the wrist.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

    Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.

  • A person works in Sionna Therapeutics' lab.
    Image attribution tooltip
    Permission granted by Sionna Therapeutics
    Image attribution tooltip

    Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

    Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines

    Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.

  • gene editing crispr cartoon
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A // Gene editing

    Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses

    The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years. 

  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

    Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

  • This image shows a digital illustration of red blood cells flowing through a blood vessel. The red blood cells are shown in a close-up view, and the vessel is shown as a red, translucent tube.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Vaderis hauls in $152M to test an AKT-targeting drug

    The startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.

  • a photo of Epicrispr Biotechnologies CEO Amber Salzman standing in a white lab coat facing the camera with a woman behind her to her left in a white lab coat with black glasses holding a tube and syringe, and a woman in a white labcoat behind to the right facing the right touching lab tools.
    Image attribution tooltip
    Permission granted by Epicrispr Biotechnologies
    Image attribution tooltip
    Emerging biotech

    Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

    The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.

  • A sign for Jazz Pharmaceuticals is displayed at the ASCO annual meeting in Chicago on June 2, 2018.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

    Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.

  • Europe's JUPITER supercomputer. Big pharma companies are racing to use AI and supercomputing in drug R&D
    Image attribution tooltip
    Sascha Schuermann/Getty Images via Getty Images
    Image attribution tooltip

    Why Big Pharma is chasing the industry’s most-powerful supercomputer

    Bristol Myers Squibb is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.

  • The building features a modern glass façade with the Nasdaq logo prominently displayed. Surrounding the structure are other commercial buildings and digital billboards, which are characteristic of the vibrant Times Square environment.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Pain drugs

    Latigo IPO raises nearly $350M for pain drug development

    The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Drug startups have banked $6 billion in IPOs so far in 2026, more than the combined amount raised by this point in the previous four years.

    Updated Aug. 7, 2026
  • Close up of eye with retina visible
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

    Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.” 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

    Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Takeda approval ushers in new wave of sleep drugs

    An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins.

  • The logo of the Food and Drug Administration is seen in a close-up view of the agency's website.
    Image attribution tooltip
    Mario Guti via Getty Images
    Image attribution tooltip

    Replimune rebounds to win FDA approval of melanoma drug

    The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.

  • A cooler for an organ transplant sits on a cart in an operating room, as a hospital staffer works behind.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip
    Emerging biotech

    With $263M, LifeMine unearths a new drug for organ transplants

    Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs. 

  • Portrait of a brown-haired man smiling at the camera.
    Image attribution tooltip
    Permission granted by HI-Bio
    Image attribution tooltip
    IPO window

    Cardiac drug developer Braveheart banks more than $382M in IPO

    Braveheart’s offering was the largest among four biotech IPOs that collectively raised more than $1 billion from public investors last week.

    Updated Aug. 6, 2026
  • Engraving on a wall reads "wall street."
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch

    Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

  • A Moderna logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip
    Vaccines

    FDA approves Moderna’s mRNA flu vaccine

    The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.

    FDA
  • A picture of CDC director Erica Schwartz testifying at a Senate confirmation hearing.
    Image attribution tooltip
    Finn Gomez / Staff via Getty Images
    Image attribution tooltip
    Vaccines

    Erica Schwartz confirmed as next CDC director

    Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

    FDA